CN117624188A - 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 - Google Patents

作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 Download PDF

Info

Publication number
CN117624188A
CN117624188A CN202311341729.0A CN202311341729A CN117624188A CN 117624188 A CN117624188 A CN 117624188A CN 202311341729 A CN202311341729 A CN 202311341729A CN 117624188 A CN117624188 A CN 117624188A
Authority
CN
China
Prior art keywords
alkyl
group
thia
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311341729.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·埃克哈特
M·K·威尔瓦赫
J·普雷斯特尔
F·孔特斯
L·托马斯
C·S·陶特曼
D·维登迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN117624188A publication Critical patent/CN117624188A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202311341729.0A 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物 Pending CN117624188A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20207719.4 2020-11-16
EP20207719 2020-11-16
CN202180076849.5A CN116745300A (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180076849.5A Division CN116745300A (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Publications (1)

Publication Number Publication Date
CN117624188A true CN117624188A (zh) 2024-03-01

Family

ID=73543025

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311341729.0A Pending CN117624188A (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物
CN202180076849.5A Pending CN116745300A (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180076849.5A Pending CN116745300A (zh) 2020-11-16 2021-11-12 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Country Status (19)

Country Link
US (2) US11766443B2 (https=)
EP (1) EP4244229A1 (https=)
JP (2) JP7465368B2 (https=)
KR (1) KR20230109692A (https=)
CN (2) CN117624188A (https=)
AR (1) AR124070A1 (https=)
AU (1) AU2021379248A1 (https=)
CA (1) CA3200710A1 (https=)
CL (2) CL2023001361A1 (https=)
CO (1) CO2023005894A2 (https=)
CR (1) CR20230211A (https=)
DO (1) DOP2023000090A (https=)
EC (1) ECSP23036210A (https=)
IL (1) IL302769A (https=)
JO (1) JOP20230107A1 (https=)
MX (1) MX2023005678A (https=)
PE (1) PE20231855A1 (https=)
SA (1) SA523440809B1 (https=)
WO (1) WO2022101377A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1034722A (zh) * 1987-12-18 1989-08-16 弗·哈夫曼-拉罗切有限公司 三唑[4，3-a][1，4]苯并二氮杂草和噻吩并[3，2-f][1，2，4]三唑并[4，3-a][1，4]二氮杂草
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
JPS62181282A (ja) * 1986-01-21 1987-08-08 ベ−リンガ−　インゲルハイム　コマンデイツト　ゲゼルシヤフト チエノ−１，４−ジアゼピン
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1034722A (zh) * 1987-12-18 1989-08-16 弗·哈夫曼-拉罗切有限公司 三唑[4，3-a][1，4]苯并二氮杂草和噻吩并[3，2-f][1，2，4]三唑并[4，3-a][1，4]二氮杂草
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM[ONLINE] NCBI: "Database accession no.147780900", 《DATABASE PUBCHEM[ONLINE] NCBI》, 12 August 2020 (2020-08-12), pages 1 *
KARL HEINZ WEBER ET AL.: "Hetrazepines as Antagonists of Platelet Activating Factor", 《MEDICINAL RESEARCH REVIEWS》, vol. 9, no. 2, 31 December 1989 (1989-12-31), pages 181 - 218 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Also Published As

Publication number Publication date
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
JP2024099528A (ja) 2024-07-25
US11766443B2 (en) 2023-09-26
US20220160725A1 (en) 2022-05-26
AR124070A1 (es) 2023-02-08
ECSP23036210A (es) 2023-06-30
JP2023521200A (ja) 2023-05-23
PE20231855A1 (es) 2023-11-21
JOP20230107A1 (ar) 2023-05-16
EP4244229A1 (en) 2023-09-20
US20230355638A1 (en) 2023-11-09
CL2024000317A1 (es) 2024-07-12
JP7465368B2 (ja) 2024-04-10
KR20230109692A (ko) 2023-07-20
MX2023005678A (es) 2023-05-26
IL302769A (en) 2023-07-01
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
WO2022101377A1 (en) 2022-05-19
CR20230211A (es) 2023-07-13
CL2023001361A1 (es) 2023-11-03
SA523440809B1 (ar) 2024-10-08
TW202237620A (zh) 2022-10-01
CN116745300A (zh) 2023-09-12
AU2021379248A1 (en) 2023-06-22
AU2021379248A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
TW201927765A (zh) 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸
JP2021506859A (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
CN113039181B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
CN112702998A (zh) 作为lpa拮抗剂的环庚酸
JP7703587B2 (ja) 血漿カリクレイン阻害剤としての複素芳香族カルボキシアミド誘導体
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2014101295A2 (zh) 一种詹纳斯激酶（JAKs）抑制活性的异恶唑衍生物
TW202023550A (zh) 作為vanin抑制劑之雜芳族化合物
EP1301516A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
CN115087652B (zh) 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
JP7810743B2 (ja) 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体
TWI913356B (zh) 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物
CN112839711A (zh) 作为血浆激肽释放酶抑制剂的苯基四唑衍生物
EA048242B1 (ru) Циклопентатиофенкарбоксамидные производные в качестве антагонистов рецептора фактора активации тромбоцитов
CN118414340A (zh) 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination